12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xgeva denosumab regulatory update

The U.K.'s NICE issued final guidance recommending the use of Xgeva denosumab from Amgen to prevent skeletal-related events (SREs) in patients with bone metastases from breast cancer; and from solid tumors other than prostate cancer if bisphosphonates would otherwise be prescribed. The recommendation is contingent on Amgen providing Xgeva at an undisclosed discount under...

Read the full 248 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >